Litigation

Celgene Corporation v. Sun Pharmaceutical Industries et al.

settled

Auto-generating section 1 of 4: Case overview & background…

Each section takes ~30-60s with web-search grounding. Keep this tab open — sections will fill in below as they complete.

Court
D.N.J.

Patents at issue (3)

7977357
8193219
8431598

Summary

Celgene and Sun settled a Hatch-Waxman lenalidomide action in July 2021. The asserted patents identified in the settlement were U.S. 7,977,357, 8,193,219, and 8,431,598, with volume-limited sales after March 2022 and unlimited after Jan. 2026; the Hatch-Waxman actions were dismissed.

Case overview & background

Plain-language overview of the case: parties, accused product, patents at issue, and why the suit matters.

Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).

Key legal developments & outcome

Major rulings, motions, claim construction, settlements, and the present posture or final disposition.

Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).

Plaintiff representatives

Counsel of record for the plaintiff(s): attorneys, firms, and roles (lead counsel, of counsel, local counsel).

Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).

Defendant representatives

Counsel of record for the defendant(s): attorneys, firms, and roles (lead counsel, of counsel, local counsel).

Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).

Record id: 7977357-celgene-corporation-v-sun-pharmaceutical-industries-sun-pharma-and-u-s-s · edit in Admin